Oncology Practice Management Issues


April 2015, Vol 5, No 3

Cost of Regorafenib versus Benefit Analyzed in Patients with Metastatic Colorectal Cancer

Chase Doyle

Gastrointestinal Cancers Symposium

According to a recent cost-effectiveness analysis, third-line therapy with regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (CRC) far ­exceeded accepted willingness-to-pay thresholds based on incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALYs). Presented at the 2015 Gastrointestinal [ Read More ]